SlideShare a Scribd company logo
May 28 – 30, 2015, Montréal, Québec
Contrast Nephropathy
Swapnil Hiremath, MD, MPH
@hswapnil
Nephrologist
The Ottawa Hospital
University of Ottawa
Ottawa Hospital Research Institute
May 28 – 30, 2015, Montréal, Québec
Disclosure Statement: With a Conflict of Interest
Financial:
• Study funding: GE Healthcare is funding an economic analysis to study the
impact of osmolality of contrast medium and acute kidney injury
• I own no stock or securities nor do I serve or have served as a consultant
for any drug or device manufacturer
Others:
• I am the PI of an ongoing trial examining oral hydration (vs IV) to prevent
contrast nephropathy
• I am a co-author of the Canadian Association of Radiology (CAR)
guidelines
CAMRT joint Congress May 2015
Objectives
At the end of this talk, the listener will
• Identify patients who are at high risk of contrast
nephropathy
• Know what to order to minimize risk of
contrast nephropathy
CAMRT joint Congress May 2015
What is Contrast
Nephropathy*?
*Now known as
Contrast-induced
Acute Kidney Injury
Following Contrast
exposure:
Arterial (cardiac cath,
arteriograms)
Venous (CT Scans)
CAMRT joint Congress May 2015
What is Contrast
Nephropathy*?
• Acute Kidney Injury,
defined as:
• Rise in creatinine of
25%
• Rise in creatinine of
44 micromol/L
• A much smaller
proportion: Dialysis
or Death
*Now known as
Contrast-induced
Acute Kidney Injury
Following Contrast
exposure:
Arterial (cardiac cath,
arteriograms)
Venous (CT Scans)
CAMRT joint Congress May 2015
Case
CAMRT joint Congress May 2015
Case
• 59 year old gentleman, DM2
• Worsening angina
• Cr 170 at baseline (eGFR 38)
CAMRT joint Congress May 2015
Case
• 59 year old gentleman, DM2
• Worsening angina
• Cr 170 at baseline (eGFR 38)
CAMRT joint Congress May 2015
Case
• 59 year old gentleman, DM2
• Worsening angina
• Cr 170 at baseline (eGFR 38)
CAMRT joint Congress May 2015
Pathophysiology
from: cJASN Jan 2008
CAMRT joint Congress May 2015
Pathophysiology
from: cJASN Jan 2008
CAMRT joint Congress May 2015
Pathophysiology
• Courtesy Prof Persson, Berlin
CAMRT joint Congress May 2015
Which patients are at risk?
CAMRT joint Congress May 2015
Which patients are at risk?
• Arterial contrast (Cardiac Catheterization,
Angiograms) >>Venous Contrast (Contrast
enhanced CT scans)
CAMRT joint Congress May 2015
Which patients are at risk?
• Arterial contrast (Cardiac Catheterization,
Angiograms) >>Venous Contrast (Contrast
enhanced CT scans)
• Diabetes, Dehydration
CAMRT joint Congress May 2015
Which patients are at risk?
• Arterial contrast (Cardiac Catheterization,
Angiograms) >>Venous Contrast (Contrast
enhanced CT scans)
• Diabetes, Dehydration
• Severe Chronic Kidney Disease (eGFR <
30, stage 4 and 5 CKD)
CAMRT joint Congress May 2015
How should we prevent Contrast - AKI?
Literature Roundup
>8000 publications
14 + 57 + 22 + 18
=113 RCTs
(4 interventions)
3412 with RCT
filter
42 Meta-
analyses
CAMRT joint Congress May 2015
How should we prevent Contrast - AKI?
Literature Roundup
>8000 publications
14 + 57 + 22 + 18
=113 RCTs
(4 interventions)
3412 with RCT
filter
42 Meta-
analyses
+ 82 studies
currently recruiting
(per
Clinicaltrials.gov)
CAMRT joint Congress May 2015
N-Acetyl Cysteine
(mucomyst)
CAMRT joint Congress May 2015
N-Acetyl Cysteine:
Mixed Evidence?
Gonzales et al, BMC Medicine, 2007
CAMRT joint Congress May 2015
N-Acetyl Cysteine:
Mixed Evidence?
Gonzales et al, BMC Medicine, 2007
CAMRT joint Congress May 2015
N-Acetyl Cysteine:
Mixed Evidence?
Gonzales et al, BMC Medicine, 2007
CAMRT joint Congress May 2015
N-Acetyl Cysteine:
Definitive Evidence
CAMRT joint Congress May 2015
N-Acetyl Cysteine:
Definitive Evidence
CAMRT joint Congress May 2015
N-Acetyl Cysteine:
Definitive Evidence
ACT study, Berwanger et al,
Circulation, 2011
N = 2272
CAMRT joint Congress May 2015
N-Acetyl Cysteine:
Definitive Evidence
ACT study, Berwanger et al,
Circulation, 2011
N = 2272
CAMRT joint Congress May 2015
Volume Expansion: Bicarb
CAMRT joint Congress May 2015
Volume Expansion: Bicarb
CAMRT joint Congress May 2015
Volume Expansion: Bicarb
Merten et al, JAMA
2004
N = 119
CAMRT joint Congress May 2015
Volume Expansion: Bicarb
or Saline?
CAMRT joint Congress May 2015
Volume Expansion: Bicarb
or Saline?
CAMRT joint Congress May 2015
Volume Expansion: Bicarb
or Saline?
CAMRT joint Congress May 2015
Volume Expansion: Bicarb
or Saline?
CAMRT joint Congress May 2015
Oral hydration?
Source: Hiremath et al, PLoS One, 2013
Small number of studies
Ongoing trial at Ottawa
CAMRT joint Congress May 2015
Safer Contrast Media
CAMRT joint Congress May 2015
Safer Contrast MediaIonicity Relative
Osmolality
Osmolality
(mOsm/kg H20)
Examples
Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate,
Metrizoate,
Iodamide, Ioxithalamate
Ionic dimers Low osmolality 600 Ioxaglate
Nonionic monomers Low osmolality 500 – 700 Iopamidol,
Iohexol,
Iomeprol,
Iopentol,
Iopromide,
Ioversol,
Ioxitol,
Metrizamide
Nonionic dimers Iso-osmolal 290-320 Iodixanol,
Iotrolan
CAMRT joint Congress May 2015
Safer Contrast MediaIonicity Relative
Osmolality
Osmolality
(mOsm/kg H20)
Examples
Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate,
Metrizoate,
Iodamide, Ioxithalamate
Ionic dimers Low osmolality 600 Ioxaglate
Nonionic monomers Low osmolality 500 – 700 Iopamidol,
Iohexol,
Iomeprol,
Iopentol,
Iopromide,
Ioversol,
Ioxitol,
Metrizamide
Nonionic dimers Iso-osmolal 290-320 Iodixanol,
Iotrolan
CAMRT joint Congress May 2015
Safer Contrast MediaIonicity Relative
Osmolality
Osmolality
(mOsm/kg H20)
Examples
Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate,
Metrizoate,
Iodamide, Ioxithalamate
Ionic dimers Low osmolality 600 Ioxaglate
Nonionic monomers Low osmolality 500 – 700 Iopamidol,
Iohexol,
Iomeprol,
Iopentol,
Iopromide,
Ioversol,
Ioxitol,
Metrizamide
Nonionic dimers Iso-osmolal 290-320 Iodixanol,
Iotrolan
CAMRT joint Congress May 2015
Safer Contrast MediaIonicity Relative
Osmolality
Osmolality
(mOsm/kg H20)
Examples
Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate,
Metrizoate,
Iodamide, Ioxithalamate
Ionic dimers Low osmolality 600 Ioxaglate
Nonionic monomers Low osmolality 500 – 700 Iopamidol,
Iohexol,
Iomeprol,
Iopentol,
Iopromide,
Ioversol,
Ioxitol,
Metrizamide
Nonionic dimers Iso-osmolal 290-320 Iodixanol,
Iotrolan
CAMRT joint Congress May 2015
Safer Contrast MediaIonicity Relative
Osmolality
Osmolality
(mOsm/kg H20)
Examples
Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate,
Metrizoate,
Iodamide, Ioxithalamate
Ionic dimers Low osmolality 600 Ioxaglate
Nonionic monomers Low osmolality 500 – 700 Iopamidol,
Iohexol,
Iomeprol,
Iopentol,
Iopromide,
Ioversol,
Ioxitol,
Metrizamide
Nonionic dimers Iso-osmolal 290-320 Iodixanol,
Iotrolan
CAMRT joint Congress May 2015
Safer Contrast Media
• Low Osmolar >>safer then High Osmolar (Barrett
et al, Radiology 1993)
Ionicity Relative
Osmolality
Osmolality
(mOsm/kg H20)
Examples
Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate,
Metrizoate,
Iodamide, Ioxithalamate
Ionic dimers Low osmolality 600 Ioxaglate
Nonionic monomers Low osmolality 500 – 700 Iopamidol,
Iohexol,
Iomeprol,
Iopentol,
Iopromide,
Ioversol,
Ioxitol,
Metrizamide
Nonionic dimers Iso-osmolal 290-320 Iodixanol,
Iotrolan
CAMRT joint Congress May 2015
Safer Contrast Media
• Low Osmolar >>safer then High Osmolar (Barrett
et al, Radiology 1993)
• Iso-osmolar versus Low osmolar?
Ionicity Relative
Osmolality
Osmolality
(mOsm/kg H20)
Examples
Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate,
Metrizoate,
Iodamide, Ioxithalamate
Ionic dimers Low osmolality 600 Ioxaglate
Nonionic monomers Low osmolality 500 – 700 Iopamidol,
Iohexol,
Iomeprol,
Iopentol,
Iopromide,
Ioversol,
Ioxitol,
Metrizamide
Nonionic dimers Iso-osmolal 290-320 Iodixanol,
Iotrolan
CAMRT joint Congress May 2015
Use Safer Contrast media
CAMRT joint Congress May 2015
Use Safer Contrast media
CAMRT joint Congress May 2015
Use Safer Contrast media
Aspelin et al, New Engl J Med,
2003
N = 129
CAMRT joint Congress May 2015
Is Iodixanol truly
superior?
CAMRT joint Congress May 2015
Is Iodixanol truly
superior?
CAMRT joint Congress May 2015
Is Iodixanol truly
superior?
CARE study, Solomon et al,
Circulation, 2007
N = 414
CAMRT joint Congress May 2015
Is Iodixanol truly
superior?
CAMRT joint Congress May 2015
Is Iodixanol truly
superior?
CAMRT joint Congress May 2015
Meta-Analysis: LOCM
vs IsoCM
CAMRT joint Congress May 2015
Meta-Analysis: LOCM
vs IsoCM
CAMRT joint Congress May 2015
Meta-Analysis: LOCM
vs IsoCM
CAMRT joint Congress May 2015
Meta-Analysis: LOCM
vs IsoCM
CAMRT joint Congress May 2015
Iodixanol vs
Iohexol
CAMRT joint Congress May 2015
Iodixanol vs
Other LOCMs
CAMRT joint Congress May 2015
What about Dialysis to
remove contrast?
CAMRT joint Congress May 2015
What about Dialysis to
remove contrast?
Cruz et al,AJKD,
2007
CAMRT joint Congress May 2015
What about Dialysis to
remove contrast?
Cruz et al,AJKD,
2007
CAMRT joint Congress May 2015
What about Dialysis to
remove contrast?
Marenzi et al, New Engl J Med,
2003
N = 114
Cruz et al,AJKD,
2007
CAMRT joint Congress May 2015
What about Dialysis to
remove contrast?
CAMRT joint Congress May 2015
What about Dialysis to
remove contrast?
CAMRT joint Congress May 2015
What about Dialysis to
remove contrast?
Reinecke et al, Clin Res
Cardiol, 2007
CAMRT joint Congress May 2015
Comparison of Effect Sizes
CAMRT joint Congress May 2015
Comparison of Effect Sizes
Intervention First Study
Best
Study
N-Acetyl Cysteine 0.1 1.01
Bicarb-based Hydration 0.125 0.94
Dialysis after Contrast 0.1 0.90
Iso-osmolar vs low-
osmolar Contrast
0.09 1.13
CAMRT joint Congress May 2015
Comparison of Effect Sizes
Intervention First Study
Best
Study
N-Acetyl Cysteine 0.1 1.01
Bicarb-based Hydration 0.125 0.94
Dialysis after Contrast 0.1 0.90
Iso-osmolar vs low-
osmolar Contrast
0.09 1.13
CAMRT joint Congress May 2015
Comparison of Effect Sizes
Intervention First Study
Best
Study
N-Acetyl Cysteine 0.1 1.01
Bicarb-based Hydration 0.125 0.94
Dialysis after Contrast 0.1 0.90
Iso-osmolar vs low-
osmolar Contrast
0.09 1.13
CAMRT joint Congress May 2015
Comparison of Effect Sizes
Intervention
First
Study
Best
Study
N-Acetyl
Cysteine
0.1
NEJM
1.01
CirculationN-Acetyl
Cysteine
0.1
N = 83
1.01
N =2400
Bicarb-based
Hydration
0.125
JAMA
0.94
JAMABicarb-based
Hydration
0.125
N =119
0.94
N = 353
Dialysis after
Contrast
0.1
NEJM
0.90
CRCDialysis after
Contrast
0.1
N = 114
0.90
N = 424
Iso-osmolar
Contrast
0.09
NEJM
1.13
JACCIso-osmolar
Contrast
0.09
N = 129
1.13
N = 418
CAMRT joint Congress May 2015
Contrast media
DoesVenous Contrast
cause Acute Kidney
Injury?
CAMRT joint Congress May 2015
Contrast media Acute Kidney Injury
DoesVenous Contrast
cause Acute Kidney
Injury?
CAMRT joint Congress May 2015
Contrast media Acute Kidney Injury
DoesVenous Contrast
cause Acute Kidney
Injury?
CAMRT joint Congress May 2015
Contrast media Acute Kidney Injury
Sepsis
Cardiogenic Shock
DoesVenous Contrast
cause Acute Kidney
Injury?
CAMRT joint Congress May 2015
Contrast media Acute Kidney Injury
Sepsis
Cardiogenic Shock
DoesVenous Contrast
cause Acute Kidney
Injury?
CAMRT joint Congress May 2015
Contrast-
induced
Contrast media Acute Kidney Injury
Sepsis
Cardiogenic Shock
DoesVenous Contrast
cause Acute Kidney
Injury?
CAMRT joint Congress May 2015
Contrast-
associated
Contrast media Acute Kidney Injury
Sepsis
Cardiogenic Shock
DoesVenous Contrast
cause Acute Kidney
Injury?
CAMRT joint Congress May 2015
DoesVenous Contrast
Cause AKI?
Source: Radiology, 2014
CAMRT joint Congress May 2015
DoesVenous Contrast
Cause AKI?
Source: Radiology, 2014
CAMRT joint Congress May 2015
Others
• If hydration helps, so will stopping diuretics
• Potentially nephrotoxic medications: NSAIDs,
others
• RAS Blockade? (ACE inhibitors,Angiotensin
receptor blockers, renin inhibitors,
spironolactone)
• Statins
CAMRT joint Congress May 2015
Metformin and Contrast?
CAMRT joint Congress May 2015
Metformin and Contrast?
• Metformin is NOT nephrotoxic;
phenformin, its predecessor was banned
for causing lactic acidosis. Case reports
exist with metformin as well
CAMRT joint Congress May 2015
Metformin and Contrast?
• Metformin is NOT nephrotoxic;
phenformin, its predecessor was banned
for causing lactic acidosis. Case reports
exist with metformin as well
• So, if a patient is on metformin AND
CAMRT joint Congress May 2015
Metformin and Contrast?
• Metformin is NOT nephrotoxic;
phenformin, its predecessor was banned
for causing lactic acidosis. Case reports
exist with metformin as well
• So, if a patient is on metformin AND
• Is given contrast AND
CAMRT joint Congress May 2015
Metformin and Contrast?
• Metformin is NOT nephrotoxic;
phenformin, its predecessor was banned
for causing lactic acidosis. Case reports
exist with metformin as well
• So, if a patient is on metformin AND
• Is given contrast AND
• Develops severe AKI (GFR <20) AND
CAMRT joint Congress May 2015
Metformin and Contrast?
• Metformin is NOT nephrotoxic;
phenformin, its predecessor was banned
for causing lactic acidosis. Case reports
exist with metformin as well
• So, if a patient is on metformin AND
• Is given contrast AND
• Develops severe AKI (GFR <20) AND
• Metformin is not stopped THEN
CAMRT joint Congress May 2015
Metformin and Contrast?
• Metformin is NOT nephrotoxic;
phenformin, its predecessor was banned
for causing lactic acidosis. Case reports
exist with metformin as well
• So, if a patient is on metformin AND
• Is given contrast AND
• Develops severe AKI (GFR <20) AND
• Metformin is not stopped THEN
• There is a possibility of lactic acidosis
CAMRT joint Congress May 2015
Metformin and Contrast?
‘ The legacy of phenformin, anecdotes,
scattered case reports, product inserts
and medicolegal anxieties are more at
the heart of this issue than scientific
fact’ - Gerald Pond, Radiology, 2001
CAMRT joint Congress May 2015
Summary
CAMRT joint Congress May 2015
Summary
• Contrast procedures have become safer with
time
CAMRT joint Congress May 2015
Summary
• Contrast procedures have become safer with
time
• IV (eg CT scans) contrast is considerably less
harmful than IA contrast (eg cardiac cath)
CAMRT joint Congress May 2015
Summary
• Contrast procedures have become safer with
time
• IV (eg CT scans) contrast is considerably less
harmful than IA contrast (eg cardiac cath)
• CKD stage 4 & 5 (GFR < 30) might still be at risk
of AKI with CT Scans
CAMRT joint Congress May 2015
Summary
• Contrast procedures have become safer with
time
• IV (eg CT scans) contrast is considerably less
harmful than IA contrast (eg cardiac cath)
• CKD stage 4 & 5 (GFR < 30) might still be at risk
of AKI with CT Scans
• Most prophylactic measures (bicarb, NAC,
dialysis) don’t work; except for volume expansion
CAMRT joint Congress May 2015
Thank you
• Email:
shiremath@toh.on.ca
• Twitter: @hswapnil
• https://about.me/
swapnil.hiremath

More Related Content

Viewers also liked

02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
guest2379201
 
Diabetic ketoacidosis
Diabetic ketoacidosisDiabetic ketoacidosis
Diabetic ketoacidosis
Kimberly Schaible
 
Acute Renal Failure Lecture
Acute Renal Failure LectureAcute Renal Failure Lecture
Acute Renal Failure Lecture
Joel Topf
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced Nephropathy
Waleed El-Refaey
 
Approach to a Patient with Acute kidney injury
Approach to a Patient with Acute kidney injury Approach to a Patient with Acute kidney injury
Approach to a Patient with Acute kidney injury
AIIMS, New Delhi, India
 
Diabetic ketoacidosis: a case study
Diabetic ketoacidosis: a case studyDiabetic ketoacidosis: a case study
Diabetic ketoacidosis: a case study
Lyndon Woytuck
 
Acute kidney Injury
Acute kidney InjuryAcute kidney Injury
Acute kidney Injury
Rajanna Sreedhara
 
Dka diabetic ketoacidosis managment
Dka diabetic ketoacidosis managmentDka diabetic ketoacidosis managment
Dka diabetic ketoacidosis managment
Eyad Miskawi
 
A Case of Acute Kidney Injury (ARF)
A Case of Acute Kidney Injury (ARF)A Case of Acute Kidney Injury (ARF)
A Case of Acute Kidney Injury (ARF)
Stanley Medical College, Department of Medicine
 
Diabetic Keto acidosis DKA
Diabetic Keto acidosis DKADiabetic Keto acidosis DKA
Diabetic Keto acidosis DKA
Farhan Shaikh
 
CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)
CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)
CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)
Aaromal Satheesh
 
Medios de contraste en imagenologia.
Medios de contraste en imagenologia.Medios de contraste en imagenologia.
Medios de contraste en imagenologia.
Agustina Chavez Sanchez
 
DIABETIC KETOACIDOSIS PRESENTATION BY ROOMA KHALID
DIABETIC KETOACIDOSIS  PRESENTATION BY ROOMA KHALIDDIABETIC KETOACIDOSIS  PRESENTATION BY ROOMA KHALID
DIABETIC KETOACIDOSIS PRESENTATION BY ROOMA KHALID
Rooma Khalid
 
Acute Kidney Injury
Acute Kidney InjuryAcute Kidney Injury
Acute Kidney Injury
Dr.Mahmoud Abbas
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
Siddhesh Kalantri
 
The crash cart
The crash cartThe crash cart
The crash cart
Jaber Nami
 

Viewers also liked (16)

02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
 
Diabetic ketoacidosis
Diabetic ketoacidosisDiabetic ketoacidosis
Diabetic ketoacidosis
 
Acute Renal Failure Lecture
Acute Renal Failure LectureAcute Renal Failure Lecture
Acute Renal Failure Lecture
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced Nephropathy
 
Approach to a Patient with Acute kidney injury
Approach to a Patient with Acute kidney injury Approach to a Patient with Acute kidney injury
Approach to a Patient with Acute kidney injury
 
Diabetic ketoacidosis: a case study
Diabetic ketoacidosis: a case studyDiabetic ketoacidosis: a case study
Diabetic ketoacidosis: a case study
 
Acute kidney Injury
Acute kidney InjuryAcute kidney Injury
Acute kidney Injury
 
Dka diabetic ketoacidosis managment
Dka diabetic ketoacidosis managmentDka diabetic ketoacidosis managment
Dka diabetic ketoacidosis managment
 
A Case of Acute Kidney Injury (ARF)
A Case of Acute Kidney Injury (ARF)A Case of Acute Kidney Injury (ARF)
A Case of Acute Kidney Injury (ARF)
 
Diabetic Keto acidosis DKA
Diabetic Keto acidosis DKADiabetic Keto acidosis DKA
Diabetic Keto acidosis DKA
 
CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)
CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)
CASE PRESENTATION ON DIABETIC KETOACIDOSIS (DKA)
 
Medios de contraste en imagenologia.
Medios de contraste en imagenologia.Medios de contraste en imagenologia.
Medios de contraste en imagenologia.
 
DIABETIC KETOACIDOSIS PRESENTATION BY ROOMA KHALID
DIABETIC KETOACIDOSIS  PRESENTATION BY ROOMA KHALIDDIABETIC KETOACIDOSIS  PRESENTATION BY ROOMA KHALID
DIABETIC KETOACIDOSIS PRESENTATION BY ROOMA KHALID
 
Acute Kidney Injury
Acute Kidney InjuryAcute Kidney Injury
Acute Kidney Injury
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
The crash cart
The crash cartThe crash cart
The crash cart
 

Similar to Contrast-induced Acute Kidney Injury

Humanitarian aid and access to haemophilia care
Humanitarian aid and access to haemophilia careHumanitarian aid and access to haemophilia care
Humanitarian aid and access to haemophilia care
Albert Farrugia
 
A Critical Appraisal of Nephrology RCTs 2017
A Critical Appraisal of Nephrology RCTs 2017A Critical Appraisal of Nephrology RCTs 2017
A Critical Appraisal of Nephrology RCTs 2017
Meguid Nahas
 
Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...
Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...
Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...
Alexander Kharlamov
 
2015年7月刊:《欧洲介入杂志》十周年庆
2015年7月刊:《欧洲介入杂志》十周年庆2015年7月刊:《欧洲介入杂志》十周年庆
2015年7月刊:《欧洲介入杂志》十周年庆
Rahab Jin
 
MONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptx
MONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptxMONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptx
MONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptx
RodrigoHerrera235097
 
WhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdf
WhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdfWhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdf
WhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdf
kurniaramadani
 
WS3_AssessmentTools_Varnäs
WS3_AssessmentTools_VarnäsWS3_AssessmentTools_Varnäs
WS3_AssessmentTools_Varnäs
actiontown
 
Strive Teleconf Presentation Aug10 2005
Strive Teleconf Presentation Aug10 2005Strive Teleconf Presentation Aug10 2005
Strive Teleconf Presentation Aug10 2005
MedicineAndHealthCancer
 
Publications from the EuroCTO registry
Publications from the EuroCTO registryPublications from the EuroCTO registry
Publications from the EuroCTO registry
Euro CTO Club
 
Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo
Antonio Raviele
 
ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.
SMACC Conference
 
What does research tell us about alcohol related health risks
What does research tell us about alcohol related health risksWhat does research tell us about alcohol related health risks
What does research tell us about alcohol related health risks
THL
 
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...
Fundacion EPIC
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Angioline calypso presentation (final version)
Angioline calypso presentation (final version)Angioline calypso presentation (final version)
Angioline calypso presentation (final version)
Mikhail Moris
 
Conventional Aortic Valve Replacement: Meta-analysis
Conventional Aortic Valve Replacement:Meta-analysisConventional Aortic Valve Replacement:Meta-analysis
Conventional Aortic Valve Replacement: Meta-analysis
maxrox99
 
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes A...
OHE Lunchtime Seminar:Health Technology Assessment Scientific and Outcomes A...OHE Lunchtime Seminar:Health Technology Assessment Scientific and Outcomes A...
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes A...
Office of Health Economics
 
Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017
FarragBahbah
 
Wiley Journal Citation Report (Physical Sciences)
Wiley Journal Citation Report (Physical Sciences)Wiley Journal Citation Report (Physical Sciences)
Wiley Journal Citation Report (Physical Sciences)
Wiley
 
Contrast Agents in Angiography
Contrast Agents in AngiographyContrast Agents in Angiography
Contrast Agents in Angiography
Mohammad Fathi
 

Similar to Contrast-induced Acute Kidney Injury (20)

Humanitarian aid and access to haemophilia care
Humanitarian aid and access to haemophilia careHumanitarian aid and access to haemophilia care
Humanitarian aid and access to haemophilia care
 
A Critical Appraisal of Nephrology RCTs 2017
A Critical Appraisal of Nephrology RCTs 2017A Critical Appraisal of Nephrology RCTs 2017
A Critical Appraisal of Nephrology RCTs 2017
 
Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...
Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...
Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...
 
2015年7月刊:《欧洲介入杂志》十周年庆
2015年7月刊:《欧洲介入杂志》十周年庆2015年7月刊:《欧洲介入杂志》十周年庆
2015年7月刊:《欧洲介入杂志》十周年庆
 
MONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptx
MONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptxMONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptx
MONITOREO FETAL INTRAPARTO CONSENSO FIGO 2015.pptx
 
WhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdf
WhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdfWhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdf
WhitfieldJ_Acohol2017_GenomALCbiomarkerGGTAST.pdf
 
WS3_AssessmentTools_Varnäs
WS3_AssessmentTools_VarnäsWS3_AssessmentTools_Varnäs
WS3_AssessmentTools_Varnäs
 
Strive Teleconf Presentation Aug10 2005
Strive Teleconf Presentation Aug10 2005Strive Teleconf Presentation Aug10 2005
Strive Teleconf Presentation Aug10 2005
 
Publications from the EuroCTO registry
Publications from the EuroCTO registryPublications from the EuroCTO registry
Publications from the EuroCTO registry
 
Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo Oral anticoagulants Sao Paulo
Oral anticoagulants Sao Paulo
 
ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.
 
What does research tell us about alcohol related health risks
What does research tell us about alcohol related health risksWhat does research tell us about alcohol related health risks
What does research tell us about alcohol related health risks
 
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Dyslipidemia 2016
 
Angioline calypso presentation (final version)
Angioline calypso presentation (final version)Angioline calypso presentation (final version)
Angioline calypso presentation (final version)
 
Conventional Aortic Valve Replacement: Meta-analysis
Conventional Aortic Valve Replacement:Meta-analysisConventional Aortic Valve Replacement:Meta-analysis
Conventional Aortic Valve Replacement: Meta-analysis
 
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes A...
OHE Lunchtime Seminar:Health Technology Assessment Scientific and Outcomes A...OHE Lunchtime Seminar:Health Technology Assessment Scientific and Outcomes A...
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes A...
 
Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017
 
Wiley Journal Citation Report (Physical Sciences)
Wiley Journal Citation Report (Physical Sciences)Wiley Journal Citation Report (Physical Sciences)
Wiley Journal Citation Report (Physical Sciences)
 
Contrast Agents in Angiography
Contrast Agents in AngiographyContrast Agents in Angiography
Contrast Agents in Angiography
 

Recently uploaded

The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Rahul Sen
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
SIVAVINAYAKPK
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Kunj Vihari
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Pollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdfPollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdf
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
MuhammadMuneer49
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
ayushrajshrivastava7
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
Université de Montréal
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Get New Sim
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
MuskanShingari
 

Recently uploaded (20)

The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Pollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdfPollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdf
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
 

Contrast-induced Acute Kidney Injury

  • 1. May 28 – 30, 2015, Montréal, Québec Contrast Nephropathy Swapnil Hiremath, MD, MPH @hswapnil Nephrologist The Ottawa Hospital University of Ottawa Ottawa Hospital Research Institute
  • 2. May 28 – 30, 2015, Montréal, Québec Disclosure Statement: With a Conflict of Interest Financial: • Study funding: GE Healthcare is funding an economic analysis to study the impact of osmolality of contrast medium and acute kidney injury • I own no stock or securities nor do I serve or have served as a consultant for any drug or device manufacturer Others: • I am the PI of an ongoing trial examining oral hydration (vs IV) to prevent contrast nephropathy • I am a co-author of the Canadian Association of Radiology (CAR) guidelines
  • 3. CAMRT joint Congress May 2015 Objectives At the end of this talk, the listener will • Identify patients who are at high risk of contrast nephropathy • Know what to order to minimize risk of contrast nephropathy
  • 4. CAMRT joint Congress May 2015 What is Contrast Nephropathy*? *Now known as Contrast-induced Acute Kidney Injury Following Contrast exposure: Arterial (cardiac cath, arteriograms) Venous (CT Scans)
  • 5. CAMRT joint Congress May 2015 What is Contrast Nephropathy*? • Acute Kidney Injury, defined as: • Rise in creatinine of 25% • Rise in creatinine of 44 micromol/L • A much smaller proportion: Dialysis or Death *Now known as Contrast-induced Acute Kidney Injury Following Contrast exposure: Arterial (cardiac cath, arteriograms) Venous (CT Scans)
  • 6. CAMRT joint Congress May 2015 Case
  • 7. CAMRT joint Congress May 2015 Case • 59 year old gentleman, DM2 • Worsening angina • Cr 170 at baseline (eGFR 38)
  • 8. CAMRT joint Congress May 2015 Case • 59 year old gentleman, DM2 • Worsening angina • Cr 170 at baseline (eGFR 38)
  • 9. CAMRT joint Congress May 2015 Case • 59 year old gentleman, DM2 • Worsening angina • Cr 170 at baseline (eGFR 38)
  • 10. CAMRT joint Congress May 2015 Pathophysiology from: cJASN Jan 2008
  • 11. CAMRT joint Congress May 2015 Pathophysiology from: cJASN Jan 2008
  • 12. CAMRT joint Congress May 2015 Pathophysiology • Courtesy Prof Persson, Berlin
  • 13. CAMRT joint Congress May 2015 Which patients are at risk?
  • 14. CAMRT joint Congress May 2015 Which patients are at risk? • Arterial contrast (Cardiac Catheterization, Angiograms) >>Venous Contrast (Contrast enhanced CT scans)
  • 15. CAMRT joint Congress May 2015 Which patients are at risk? • Arterial contrast (Cardiac Catheterization, Angiograms) >>Venous Contrast (Contrast enhanced CT scans) • Diabetes, Dehydration
  • 16. CAMRT joint Congress May 2015 Which patients are at risk? • Arterial contrast (Cardiac Catheterization, Angiograms) >>Venous Contrast (Contrast enhanced CT scans) • Diabetes, Dehydration • Severe Chronic Kidney Disease (eGFR < 30, stage 4 and 5 CKD)
  • 17. CAMRT joint Congress May 2015 How should we prevent Contrast - AKI? Literature Roundup >8000 publications 14 + 57 + 22 + 18 =113 RCTs (4 interventions) 3412 with RCT filter 42 Meta- analyses
  • 18. CAMRT joint Congress May 2015 How should we prevent Contrast - AKI? Literature Roundup >8000 publications 14 + 57 + 22 + 18 =113 RCTs (4 interventions) 3412 with RCT filter 42 Meta- analyses + 82 studies currently recruiting (per Clinicaltrials.gov)
  • 19. CAMRT joint Congress May 2015 N-Acetyl Cysteine (mucomyst)
  • 20. CAMRT joint Congress May 2015 N-Acetyl Cysteine: Mixed Evidence? Gonzales et al, BMC Medicine, 2007
  • 21. CAMRT joint Congress May 2015 N-Acetyl Cysteine: Mixed Evidence? Gonzales et al, BMC Medicine, 2007
  • 22. CAMRT joint Congress May 2015 N-Acetyl Cysteine: Mixed Evidence? Gonzales et al, BMC Medicine, 2007
  • 23. CAMRT joint Congress May 2015 N-Acetyl Cysteine: Definitive Evidence
  • 24. CAMRT joint Congress May 2015 N-Acetyl Cysteine: Definitive Evidence
  • 25. CAMRT joint Congress May 2015 N-Acetyl Cysteine: Definitive Evidence ACT study, Berwanger et al, Circulation, 2011 N = 2272
  • 26. CAMRT joint Congress May 2015 N-Acetyl Cysteine: Definitive Evidence ACT study, Berwanger et al, Circulation, 2011 N = 2272
  • 27. CAMRT joint Congress May 2015 Volume Expansion: Bicarb
  • 28. CAMRT joint Congress May 2015 Volume Expansion: Bicarb
  • 29. CAMRT joint Congress May 2015 Volume Expansion: Bicarb Merten et al, JAMA 2004 N = 119
  • 30. CAMRT joint Congress May 2015 Volume Expansion: Bicarb or Saline?
  • 31. CAMRT joint Congress May 2015 Volume Expansion: Bicarb or Saline?
  • 32. CAMRT joint Congress May 2015 Volume Expansion: Bicarb or Saline?
  • 33. CAMRT joint Congress May 2015 Volume Expansion: Bicarb or Saline?
  • 34. CAMRT joint Congress May 2015 Oral hydration? Source: Hiremath et al, PLoS One, 2013 Small number of studies Ongoing trial at Ottawa
  • 35. CAMRT joint Congress May 2015 Safer Contrast Media
  • 36. CAMRT joint Congress May 2015 Safer Contrast MediaIonicity Relative Osmolality Osmolality (mOsm/kg H20) Examples Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate Ionic dimers Low osmolality 600 Ioxaglate Nonionic monomers Low osmolality 500 – 700 Iopamidol, Iohexol, Iomeprol, Iopentol, Iopromide, Ioversol, Ioxitol, Metrizamide Nonionic dimers Iso-osmolal 290-320 Iodixanol, Iotrolan
  • 37. CAMRT joint Congress May 2015 Safer Contrast MediaIonicity Relative Osmolality Osmolality (mOsm/kg H20) Examples Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate Ionic dimers Low osmolality 600 Ioxaglate Nonionic monomers Low osmolality 500 – 700 Iopamidol, Iohexol, Iomeprol, Iopentol, Iopromide, Ioversol, Ioxitol, Metrizamide Nonionic dimers Iso-osmolal 290-320 Iodixanol, Iotrolan
  • 38. CAMRT joint Congress May 2015 Safer Contrast MediaIonicity Relative Osmolality Osmolality (mOsm/kg H20) Examples Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate Ionic dimers Low osmolality 600 Ioxaglate Nonionic monomers Low osmolality 500 – 700 Iopamidol, Iohexol, Iomeprol, Iopentol, Iopromide, Ioversol, Ioxitol, Metrizamide Nonionic dimers Iso-osmolal 290-320 Iodixanol, Iotrolan
  • 39. CAMRT joint Congress May 2015 Safer Contrast MediaIonicity Relative Osmolality Osmolality (mOsm/kg H20) Examples Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate Ionic dimers Low osmolality 600 Ioxaglate Nonionic monomers Low osmolality 500 – 700 Iopamidol, Iohexol, Iomeprol, Iopentol, Iopromide, Ioversol, Ioxitol, Metrizamide Nonionic dimers Iso-osmolal 290-320 Iodixanol, Iotrolan
  • 40. CAMRT joint Congress May 2015 Safer Contrast MediaIonicity Relative Osmolality Osmolality (mOsm/kg H20) Examples Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate Ionic dimers Low osmolality 600 Ioxaglate Nonionic monomers Low osmolality 500 – 700 Iopamidol, Iohexol, Iomeprol, Iopentol, Iopromide, Ioversol, Ioxitol, Metrizamide Nonionic dimers Iso-osmolal 290-320 Iodixanol, Iotrolan
  • 41. CAMRT joint Congress May 2015 Safer Contrast Media • Low Osmolar >>safer then High Osmolar (Barrett et al, Radiology 1993) Ionicity Relative Osmolality Osmolality (mOsm/kg H20) Examples Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate Ionic dimers Low osmolality 600 Ioxaglate Nonionic monomers Low osmolality 500 – 700 Iopamidol, Iohexol, Iomeprol, Iopentol, Iopromide, Ioversol, Ioxitol, Metrizamide Nonionic dimers Iso-osmolal 290-320 Iodixanol, Iotrolan
  • 42. CAMRT joint Congress May 2015 Safer Contrast Media • Low Osmolar >>safer then High Osmolar (Barrett et al, Radiology 1993) • Iso-osmolar versus Low osmolar? Ionicity Relative Osmolality Osmolality (mOsm/kg H20) Examples Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate Ionic dimers Low osmolality 600 Ioxaglate Nonionic monomers Low osmolality 500 – 700 Iopamidol, Iohexol, Iomeprol, Iopentol, Iopromide, Ioversol, Ioxitol, Metrizamide Nonionic dimers Iso-osmolal 290-320 Iodixanol, Iotrolan
  • 43. CAMRT joint Congress May 2015 Use Safer Contrast media
  • 44. CAMRT joint Congress May 2015 Use Safer Contrast media
  • 45. CAMRT joint Congress May 2015 Use Safer Contrast media Aspelin et al, New Engl J Med, 2003 N = 129
  • 46. CAMRT joint Congress May 2015 Is Iodixanol truly superior?
  • 47. CAMRT joint Congress May 2015 Is Iodixanol truly superior?
  • 48. CAMRT joint Congress May 2015 Is Iodixanol truly superior? CARE study, Solomon et al, Circulation, 2007 N = 414
  • 49. CAMRT joint Congress May 2015 Is Iodixanol truly superior?
  • 50. CAMRT joint Congress May 2015 Is Iodixanol truly superior?
  • 51. CAMRT joint Congress May 2015 Meta-Analysis: LOCM vs IsoCM
  • 52. CAMRT joint Congress May 2015 Meta-Analysis: LOCM vs IsoCM
  • 53. CAMRT joint Congress May 2015 Meta-Analysis: LOCM vs IsoCM
  • 54. CAMRT joint Congress May 2015 Meta-Analysis: LOCM vs IsoCM
  • 55. CAMRT joint Congress May 2015 Iodixanol vs Iohexol
  • 56. CAMRT joint Congress May 2015 Iodixanol vs Other LOCMs
  • 57. CAMRT joint Congress May 2015 What about Dialysis to remove contrast?
  • 58. CAMRT joint Congress May 2015 What about Dialysis to remove contrast? Cruz et al,AJKD, 2007
  • 59. CAMRT joint Congress May 2015 What about Dialysis to remove contrast? Cruz et al,AJKD, 2007
  • 60. CAMRT joint Congress May 2015 What about Dialysis to remove contrast? Marenzi et al, New Engl J Med, 2003 N = 114 Cruz et al,AJKD, 2007
  • 61. CAMRT joint Congress May 2015 What about Dialysis to remove contrast?
  • 62. CAMRT joint Congress May 2015 What about Dialysis to remove contrast?
  • 63. CAMRT joint Congress May 2015 What about Dialysis to remove contrast? Reinecke et al, Clin Res Cardiol, 2007
  • 64. CAMRT joint Congress May 2015 Comparison of Effect Sizes
  • 65. CAMRT joint Congress May 2015 Comparison of Effect Sizes Intervention First Study Best Study N-Acetyl Cysteine 0.1 1.01 Bicarb-based Hydration 0.125 0.94 Dialysis after Contrast 0.1 0.90 Iso-osmolar vs low- osmolar Contrast 0.09 1.13
  • 66. CAMRT joint Congress May 2015 Comparison of Effect Sizes Intervention First Study Best Study N-Acetyl Cysteine 0.1 1.01 Bicarb-based Hydration 0.125 0.94 Dialysis after Contrast 0.1 0.90 Iso-osmolar vs low- osmolar Contrast 0.09 1.13
  • 67. CAMRT joint Congress May 2015 Comparison of Effect Sizes Intervention First Study Best Study N-Acetyl Cysteine 0.1 1.01 Bicarb-based Hydration 0.125 0.94 Dialysis after Contrast 0.1 0.90 Iso-osmolar vs low- osmolar Contrast 0.09 1.13
  • 68. CAMRT joint Congress May 2015 Comparison of Effect Sizes Intervention First Study Best Study N-Acetyl Cysteine 0.1 NEJM 1.01 CirculationN-Acetyl Cysteine 0.1 N = 83 1.01 N =2400 Bicarb-based Hydration 0.125 JAMA 0.94 JAMABicarb-based Hydration 0.125 N =119 0.94 N = 353 Dialysis after Contrast 0.1 NEJM 0.90 CRCDialysis after Contrast 0.1 N = 114 0.90 N = 424 Iso-osmolar Contrast 0.09 NEJM 1.13 JACCIso-osmolar Contrast 0.09 N = 129 1.13 N = 418
  • 69. CAMRT joint Congress May 2015 Contrast media DoesVenous Contrast cause Acute Kidney Injury?
  • 70. CAMRT joint Congress May 2015 Contrast media Acute Kidney Injury DoesVenous Contrast cause Acute Kidney Injury?
  • 71. CAMRT joint Congress May 2015 Contrast media Acute Kidney Injury DoesVenous Contrast cause Acute Kidney Injury?
  • 72. CAMRT joint Congress May 2015 Contrast media Acute Kidney Injury Sepsis Cardiogenic Shock DoesVenous Contrast cause Acute Kidney Injury?
  • 73. CAMRT joint Congress May 2015 Contrast media Acute Kidney Injury Sepsis Cardiogenic Shock DoesVenous Contrast cause Acute Kidney Injury?
  • 74. CAMRT joint Congress May 2015 Contrast- induced Contrast media Acute Kidney Injury Sepsis Cardiogenic Shock DoesVenous Contrast cause Acute Kidney Injury?
  • 75. CAMRT joint Congress May 2015 Contrast- associated Contrast media Acute Kidney Injury Sepsis Cardiogenic Shock DoesVenous Contrast cause Acute Kidney Injury?
  • 76. CAMRT joint Congress May 2015 DoesVenous Contrast Cause AKI? Source: Radiology, 2014
  • 77. CAMRT joint Congress May 2015 DoesVenous Contrast Cause AKI? Source: Radiology, 2014
  • 78. CAMRT joint Congress May 2015 Others • If hydration helps, so will stopping diuretics • Potentially nephrotoxic medications: NSAIDs, others • RAS Blockade? (ACE inhibitors,Angiotensin receptor blockers, renin inhibitors, spironolactone) • Statins
  • 79. CAMRT joint Congress May 2015 Metformin and Contrast?
  • 80. CAMRT joint Congress May 2015 Metformin and Contrast? • Metformin is NOT nephrotoxic; phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well
  • 81. CAMRT joint Congress May 2015 Metformin and Contrast? • Metformin is NOT nephrotoxic; phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well • So, if a patient is on metformin AND
  • 82. CAMRT joint Congress May 2015 Metformin and Contrast? • Metformin is NOT nephrotoxic; phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well • So, if a patient is on metformin AND • Is given contrast AND
  • 83. CAMRT joint Congress May 2015 Metformin and Contrast? • Metformin is NOT nephrotoxic; phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well • So, if a patient is on metformin AND • Is given contrast AND • Develops severe AKI (GFR <20) AND
  • 84. CAMRT joint Congress May 2015 Metformin and Contrast? • Metformin is NOT nephrotoxic; phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well • So, if a patient is on metformin AND • Is given contrast AND • Develops severe AKI (GFR <20) AND • Metformin is not stopped THEN
  • 85. CAMRT joint Congress May 2015 Metformin and Contrast? • Metformin is NOT nephrotoxic; phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well • So, if a patient is on metformin AND • Is given contrast AND • Develops severe AKI (GFR <20) AND • Metformin is not stopped THEN • There is a possibility of lactic acidosis
  • 86. CAMRT joint Congress May 2015 Metformin and Contrast? ‘ The legacy of phenformin, anecdotes, scattered case reports, product inserts and medicolegal anxieties are more at the heart of this issue than scientific fact’ - Gerald Pond, Radiology, 2001
  • 87. CAMRT joint Congress May 2015 Summary
  • 88. CAMRT joint Congress May 2015 Summary • Contrast procedures have become safer with time
  • 89. CAMRT joint Congress May 2015 Summary • Contrast procedures have become safer with time • IV (eg CT scans) contrast is considerably less harmful than IA contrast (eg cardiac cath)
  • 90. CAMRT joint Congress May 2015 Summary • Contrast procedures have become safer with time • IV (eg CT scans) contrast is considerably less harmful than IA contrast (eg cardiac cath) • CKD stage 4 & 5 (GFR < 30) might still be at risk of AKI with CT Scans
  • 91. CAMRT joint Congress May 2015 Summary • Contrast procedures have become safer with time • IV (eg CT scans) contrast is considerably less harmful than IA contrast (eg cardiac cath) • CKD stage 4 & 5 (GFR < 30) might still be at risk of AKI with CT Scans • Most prophylactic measures (bicarb, NAC, dialysis) don’t work; except for volume expansion
  • 92. CAMRT joint Congress May 2015 Thank you • Email: shiremath@toh.on.ca • Twitter: @hswapnil • https://about.me/ swapnil.hiremath